Insulet Omnipod 5 produces positive study outcomes in type 2 population
February 14, 2025
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 diabetes.
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 diabetes.
A team of researchers has developed a “gut-on-chip” (a miniature model of the human intestine on a chip-sized device) capable of reproducing the main features of intestinal inflammation and of predicting the response of melanoma patients to immunotherapy treatment. The results have just been published in Nature Biomedical Engineering.
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted treatments known as CDK4/6 inhibitors. A new study led by Agnieszka Witkiewicz, MD, and Erik Knudsen, Ph.D., of Roswell Park Comprehensive Cancer Center and colleagues highlights the therapeutic impact of CDK2 inhibitors and is published in the journal Nature Communications.
Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily eye drops to treat glaucoma, a leading cause of blindness.
ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind to trigger cell therapies for various metabolic diseases.
BOSTON, Feb. 13, 2025 /PRNewswire/ — CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, announced today that it has received approval from Argentina’s National Administration of Drugs, Food and Medical Devices (ANMAT) to initiate the STRIDE trial, a clinical study evaluating CereVasc’s eShunt System as a treatment for normal pressure hydrocephalus (NPH).
The U.S. Senate voted 52–48 today to confirm Robert F. Kennedy Jr. as the new secretary of the U.S. Department of Health and Human Services.
Allurion Technologies (NYSE:ALUR) today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume sales.
With FDA clearance of SubtleHD™, Subtle Medical launches Subtle-ELITE™, an industry-first AI package designed to achieve superior image quality, unprecedented speed, and workflow automation
Professor Seunghyup Yoo’s research team in the Department of Electrical and Electronic Engineering developed the low-power, high-speed wearable CO2 sensor capable of stable breathing monitoring in real time.